Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification

European Journal of Cancer

Volumn 44, Issue 15, 2008, Pages 2319-2329

  Nuyten, Dimitry S A ^a   Hastie, Trevor ^b   Chi, Jen Tsan Ashley ^c   Chang, Howard Y ^b   van de Vijver, Marc J ^a,d  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Biological gene expression profiles; Breast cancer; Microarray analysis; Prognostic markers

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; EARLY CANCER; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE PROBE; HAZARD RATIO; HUMAN; HUMAN TISSUE; HYPOXIA; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NETHERLANDS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; WOUND;

BREAST NEOPLASMS; CELL HYPOXIA; EPIDEMIOLOGIC METHODS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; WOUND HEALING;

EID: 53049092584     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.07.015     Document Type: Article

References (36)

1. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 6797 (2000) 747-752
2. 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 6871 (2002) 530-536
3. Ayers M., Symmans W.F., Stec J., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil; doxorubicin; and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 12 (2004) 2284-2293
4. Chang J., Wooten E., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. The Lancet 362 9381 (2003) 362-369
5. Foekens J.A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 20 (2006)
6. Hannemann J., Oosterkamp H.M., Bosch C.A., et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 23 15 (2005) 3331-3342
7. Jansen M.P., Foekens J.A., van Staveren I.L., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23 4 (2005) 732-740
8. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 351 27 (2004) 2817-2826
9. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100 18 (2003) 10393-10398
10. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 347 25 (2002) 1999-2009
11. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 9460 (2005) 671-679
12. Dai H., van't V.L., Lamb J., et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 65 10 (2005) 4059-4066
13. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. New Engl J Med 344 8 (2001) 539-548
14. Oh D.S., Troester M.A., Usary J., et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 27 (2006)
15. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 4 (2006) 262-272
16. Chang H.Y., Sneddon J.B., Alizadeh A.A., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumours and wounds. PLoS Biol 2 2 (2004) E7
17. Chi J.T., Wang Z., Nuyten D.S., et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3 3 (2006) e47
18. Chang H.Y., Nuyten D.S., Sneddon J.B., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102 10 (2005) 3738-3743
19. Dvorak H.F. Tumours: wounds that do not heal. Similarities between tumour stroma generation and wound healing. New Engl J Med 315 26 (1986) 1650-1659
20. Iyer V.R., Eisen M.B., Ross D.T., et al. The transcriptional program in the response of human fibroblasts to serum. Science 283 5398 (1999) 83-87
21. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 6 (2004) 437-447
22. Nuyten D., Kreike B., Hart A.A., et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8 5 (2006) R62
23. Liu R., Wang X., Chen G.Y., et al. The prognostic role of a gene signature from tumourigenic breast-cancer cells. New Engl J Med 356 3 (2007) 217-226
24. Miller L.D., Smeds J., George J., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102 38 (2005 Sep 20) 13550-13555
25. West R.B., Nuyten D.S., Subramanian S., et al. Determination of stromal signatures in breast carcinoma. PLoS Biol 3 6 (2005) e187
26. Buyse M., Loi S., van't V.L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 17 (2006) 1183-1192
27. Desmedt C., Piette F., Loi S., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 11 (2007) 3207-3214
28. Adler A.S., Lin M., Horlings H., et al. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 5 (2005)
29. Wong D.J., Nuyten D.S., Regev A., et al. Revealing targeted therapy for human cancer by gene module maps. Cancer Res 68 2 (2008) 369-378
30. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 14 (2003) 8418-8423
31. MINDACT website http://www.eortc.be/services/unit/mindact/default.asp; 2006.
32. TailorX Trial website at NCI http://www.cancer.gov/clinicaltrials/digestpage/TAILORx; 2008.
33. Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumours are conserved across microarray platforms. BMC Genom 7 (2006) 96
34. Ma X.J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 6 (2004) 607-616
35. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. New Engl J Med 355 6 (2006) 560-569
36. Sotiriou C., Wirapati P., Loi S., et al. Comprehensive analysis integrating both clinicopathological and gene expression data. Proc Am Soc Clin Oncol 24 18S (2006)